$449.77
3.55% yesterday
Nasdaq, Aug 11, 10:00 pm CET

Medpace Stock price

$449.77
+126.27 39.03% 1M
+121.91 37.18% 6M
+117.54 35.38% YTD
+73.95 19.68% 1Y
+271.17 151.83% 3Y
+325.71 262.54% 5Y
+421.98 1,518.46% 10Y
+421.98 1,518.46% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+15.42 3.55%

Key metrics

Basic
Market capitalization
$12.6b
Enterprise Value
$12.6b
Net debt
positive
Cash
$46.3m
Shares outstanding
28.0m
Valuation (TTM | estimate)
P/E
31.3 | 33.4
P/S
5.7 | 4.9
EV/Sales
5.6 | 4.8
EV/FCF
21.7
P/B
73.3
Financial Health
Equity Ratio
39.3%
Return on Equity
49.0%
ROCE
136.0%
ROIC
61.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.2b | $2.5b
EBITDA
$506.5m | $536.9m
EBIT
$477.5m | $511.2m
Net Income
$418.3m | $364.2m
Free Cash Flow
$579.8m
Growth (TTM | estimate)
Revenue
9.9% | 19.2%
EBITDA
23.7% | 12.8%
EBIT
25.2% | 14.4%
Net Income
23.2% | -9.9%
Free Cash Flow
15.3%
Margin (TTM | estimate)
Gross
31.6%
EBITDA
22.7% | 21.4%
EBIT
21.4%
Net
18.7% | 14.5%
Free Cash Flow
26.0%
More
EPS
$14.4
FCF per Share
$20.7
Short interest
13.8%
Employees
6k
Rev per Employee
$360.0k
Show more

Is Medpace a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Medpace Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Medpace forecast:

2x Buy
12%
10x Hold
59%
5x Sell
29%

Analyst Opinions

17 Analysts have issued a Medpace forecast:

Buy
12%
Hold
59%
Sell
29%

Financial data from Medpace

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,232 2,232
10% 10%
100%
- Direct Costs 1,526 1,526
5% 5%
68%
706 706
22% 22%
32%
- Selling and Administrative Expenses 199 199
18% 18%
9%
- Research and Development Expense - -
-
-
506 506
24% 24%
23%
- Depreciation and Amortization 29 29
3% 3%
1%
EBIT (Operating Income) EBIT 478 478
25% 25%
21%
Net Profit 418 418
23% 23%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Medpace directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Medpace Stock News

Positive
Seeking Alpha
8 days ago
Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth, defying widespread healthcare sector pessimism. The company achieved 14% YoY revenue growth and 18.6% EBITDA growth, far surpassing expectations, and increased guidance for the year. Management accelerated opportunistic share buybacks, returning $908 million to shareholders in the first half of 2025, demo...
Positive
The Motley Fool
20 days ago
Medpace (MEDP 54.51%), a clinical contract research organization that manages drug development for pharmaceutical and biotech clients, reported its second quarter 2025 earnings on July 17, 2025. The company delivered GAAP results that topped both earnings and revenue forecasts, with GAAP revenue of $603.3 million versus the estimated $538.8 million and GAAP earnings per share (EPS) of $3.10 ver...
Neutral
Seeking Alpha
21 days ago
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants August James Troendle - Chairman & CEO Jesse J. Geiger - President Kevin M.
More Medpace News

Company Profile

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.

Head office United States
CEO August Troendle
Employees 5,900
Founded 1992
Website investor.medpace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today